Firm Advises PepStar Therapeutics on Patent Matters Related to Acquisition of Inflammation Drug Program by Gilead Sciences
Published . Updated .
This report does not map to a usual set of affected companies.
Directly affected
- GILD Gilead Sciences+7.4%
Named in this report.
Indirectly affected
- No related companies are mapped for this report yet.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| GILD | -1.91% | -1.58% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Firm Advises PepStar Therapeutics on Patent Matters Related to Acquisition of Inflammation Drug Program by Gilead Sciences Wilson Sonsini
Source: Wilson Sonsini
This story
| Company | When | Move | Status |
|---|---|---|---|
| GILD | three days earlier | -1.58% | final price |
| GILD | five days earlier | -1.91% | final price |
| GLD | three days earlier | +3.37% | final price |
| GLD | five days earlier | +3.56% | final price |
| QQQ | three days earlier | +2.96% | final price |
| QQQ | five days earlier | +1.97% | final price |
| SPY | three days earlier | +1.75% | final price |
| SPY | five days earlier | +0.89% | final price |
| TLT | three days earlier | -1.30% | final price |
| TLT | five days earlier | -2.26% | final price |
This story
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100
“Firm Advises PepStar Therapeutics on Patent Matters Related to Acquisition of Inflammation Drug Program by Gilead Sciences” scores 12 out of 100. The score uses 1 sources.